Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Other Non Operating Income (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Other Non Operating Income for 10 consecutive years, with -$8.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 506.34% year-over-year to -$8.0 million, compared with a TTM value of -$11.3 million through Dec 2025, down 2736.98%, and an annual FY2025 reading of -$11.3 million, down 2736.98% over the prior year.
  • Other Non Operating Income was -$8.0 million for Q4 2025 at Heron Therapeutics, down from -$2.1 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $2.0 million in Q4 2024 and bottomed at -$8.0 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$934578.9, with a median of -$500000.0 recorded in 2021.
  • The sharpest move saw Other Non Operating Income crashed 1156.59% in 2022, then surged 455.25% in 2024.
  • Year by year, Other Non Operating Income stood at $868000.0 in 2021, then surged by 52.3% to $1.3 million in 2022, then tumbled by 105.98% to -$79000.0 in 2023, then skyrocketed by 2596.2% to $2.0 million in 2024, then plummeted by 506.34% to -$8.0 million in 2025.
  • Business Quant data shows Other Non Operating Income for HRTX at -$8.0 million in Q4 2025, -$2.1 million in Q3 2025, and -$744000.0 in Q2 2025.